Clinical and morphological predictors of outcome in older aplastic anemia patients treated with eltrombopag.
作者信息
Fattizzo Bruno, Kulasekararaj Austin G, Hill Anita, Benson-Quarm Nana, Griffin Morag, Munir Talha, Arnold Louise, Riley Kathryn, Ireland Robin, De Lavallade Hugues, Potter Victoria, Consonni Dario, Hillmen Peter, Mufti Ghulam J, Barcellini Wilma, Marsh Judith C W
机构信息
Haematology, King's College Hospital, London, UK.
Haematology, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico di Milano, Milan, Italy.
出版信息
Haematologica. 2019 Nov;104(11):e494-e496. doi: 10.3324/haematol.2019.216374. Epub 2019 Mar 19.
Abstract
摘要
相似文献
1
Clinical and morphological predictors of outcome in older aplastic anemia patients treated with eltrombopag.接受艾曲泊帕治疗的老年再生障碍性贫血患者预后的临床和形态学预测因素
Haematologica. 2019 Nov;104(11):e494-e496. doi: 10.3324/haematol.2019.216374. Epub 2019 Mar 19.
2
Efficacy and Safety of Eltrombopag for Aplastic Anemia: A Systematic Review and Meta-analysis.促血小板生成素治疗再生障碍性贫血的疗效和安全性：系统评价和荟萃分析。
Clin Drug Investig. 2019 Feb;39(2):141-156. doi: 10.1007/s40261-018-0725-2.
3
Eltrombopag in the management of aplastic anaemia: real-world experience in a non-trial setting.艾曲泊帕在再生障碍性贫血治疗中的应用：非试验环境下的真实世界经验
Hematology. 2018 Aug;23(7):399-404. doi: 10.1080/10245332.2017.1422306. Epub 2018 Jan 5.
4
Eltrombopag restores trilineage hematopoiesis in refractory severe aplastic anemia that can be sustained on discontinuation of drug.依鲁替尼可恢复对药物停药后可维持缓解的难治性重型再生障碍性贫血的三系造血。
Blood. 2014 Mar 20;123(12):1818-25. doi: 10.1182/blood-2013-10-534743. Epub 2013 Dec 17.
5
[Safety and efficacy of the use of eltrombopag in a case of severe acquired bone marrow aplasia].[艾曲泊帕在一例严重获得性骨髓再生障碍性贫血中的使用安全性及有效性]
An Pediatr (Engl Ed). 2019 Apr;90(4):246-247. doi: 10.1016/j.anpedi.2018.04.011. Epub 2018 May 22.
6
Eltrombopag and improved hematopoiesis in refractory aplastic anemia.依鲁替尼改善再生障碍性贫血的造血功能。
N Engl J Med. 2012 Jul 5;367(1):11-9. doi: 10.1056/NEJMoa1200931.
7
Eltrombopag combined with cyclosporine may have an effect on very severe aplastic anemia.艾曲泊帕与环孢素联合使用可能对极重型再生障碍性贫血有效。
Ann Hematol. 2019 Aug;98(8):2009-2011. doi: 10.1007/s00277-019-03658-2. Epub 2019 Mar 20.
8
Eltrombopag in Immune Thrombocytopenia, Aplastic Anemia, and Myelodysplastic Syndrome: From Megakaryopoiesis to Immunomodulation.依鲁替尼在免疫性血小板减少症、再生障碍性贫血和骨髓增生异常综合征中的作用：从巨核细胞生成到免疫调节。
Drugs. 2019 Aug;79(12):1305-1319. doi: 10.1007/s40265-019-01159-0.
9
Addition of eltrombopag to immunosuppressive therapy in patients with newly diagnosed aplastic anemia.在新诊断的再生障碍性贫血患者中添加艾曲波帕进行免疫抑制治疗。
Cancer. 2018 Nov 1;124(21):4192-4201. doi: 10.1002/cncr.31658. Epub 2018 Oct 11.
10
A rare side effect: eltrombopag associated hyperpigmentation.一种罕见的副作用：艾曲泊帕相关的色素沉着。
G Ital Dermatol Venereol. 2020 Dec;155(6):803-804. doi: 10.23736/S0392-0488.19.06181-9. Epub 2019 May 14.
引用本文的文献
1
Effective treatment of refractory aplastic anemia with romiplostim after failure of multiple thrombopoietin receptor agonists: a single-center retrospective study.多种血小板生成素受体激动剂治疗失败后使用罗米司亭有效治疗难治性再生障碍性贫血：一项单中心回顾性研究
Ann Med. 2025 Dec;57(1):2514791. doi: 10.1080/07853890.2025.2514791. Epub 2025 Jun 19.
2
Determinants of COVID-19 Disease Severity-Lessons from Primary and Secondary Immune Disorders including Cancer.COVID-19 疾病严重程度的决定因素——包括癌症在内的原发性和继发性免疫紊乱的教训。
Int J Mol Sci. 2023 May 14;24(10):8746. doi: 10.3390/ijms24108746.
3
Aplastic Anemia as a Roadmap for Bone Marrow Failure: An Overview and a Clinical Workflow.再生障碍性贫血作为骨髓衰竭的路线图：概述和临床工作流程。
Int J Mol Sci. 2022 Oct 4;23(19):11765. doi: 10.3390/ijms231911765.
4
Paroxysmal nocturnal hemoglobinuria-phenotype cells predict a good response to eltrombopag in patients with refractory aplastic anemia.阵发性睡眠性血红蛋白尿表型细胞可预测难治性再生障碍性贫血患者对艾曲泊帕的良好反应。
EJHaem. 2020 Jun 29;1(1):243-248. doi: 10.1002/jha2.51. eCollection 2020 Jul.
5
Predicting Response of Severe Aplastic Anemia to Rabbit-Antithymocyte Immunoglobulin Based Immunosuppressive Therapy Combined With Eltrombopag.预测重型再生障碍性贫血对基于兔抗胸腺细胞免疫球蛋白的免疫抑制疗法联合艾曲泊帕的反应。
Front Immunol. 2022 May 26;13:884312. doi: 10.3389/fimmu.2022.884312. eCollection 2022.
6
Time and residual hematopoiesis are crucial for PNH clones escape in hepatitis-associated aplastic anemia.时间和残余造血对于 PNH 克隆在肝炎相关性再生障碍性贫血中逃逸至关重要。
Ann Hematol. 2021 Oct;100(10):2435-2441. doi: 10.1007/s00277-021-04553-5. Epub 2021 Jul 16.
7
Exosomes derived from mesenchymal stem cells regulate Treg/Th17 balance in aplastic anemia by transferring miR-23a-3p.间充质干细胞来源的外泌体通过转移 miR-23a-3p 调节再生障碍性贫血中的 Treg/Th17 平衡。
Clin Exp Med. 2021 Aug;21(3):429-437. doi: 10.1007/s10238-021-00701-3. Epub 2021 Mar 29.
8
Correlation of the Plasma Concentration of Eltrombopag With Efficacy in the Treatment of Refractory Aplastic Anemia: A Single-Centre Study in China.艾曲泊帕血浆浓度与难治性再生障碍性贫血治疗疗效的相关性：一项中国单中心研究。
Front Pharmacol. 2020 Nov 16;11:582625. doi: 10.3389/fphar.2020.582625. eCollection 2020.
9
Novel therapeutic choices in immune aplastic anemia.免疫性再生障碍性贫血的新型治疗选择
F1000Res. 2020 Sep 10;9. doi: 10.12688/f1000research.22214.1. eCollection 2020.
10
Eltrombopag is effective in patients with relapse/refractory aplastic anemia-report from a single center in China.依鲁替尼治疗复发/难治性再生障碍性贫血的疗效分析：来自中国单中心的报告。
Ann Hematol. 2020 Dec;99(12):2755-2761. doi: 10.1007/s00277-020-04266-1. Epub 2020 Sep 17.
本文引用的文献
1
Nationwide survey on the use of eltrombopag in patients with severe aplastic anemia: a report on behalf of the French Reference Center for Aplastic Anemia.一项关于艾曲波帕在重型再生障碍性贫血患者中应用的全国性调查：法国再生障碍性贫血参考中心报告。
Haematologica. 2018 Feb;103(2):212-220. doi: 10.3324/haematol.2017.176339. Epub 2017 Nov 23.
2
Incidence and outcome of acquired aplastic anemia: real-world data from patients diagnosed in Sweden from 2000-2011.获得性再生障碍性贫血的发病率和转归：来自瑞典 2000-2011 年诊断患者的真实世界数据。
Haematologica. 2017 Oct;102(10):1683-1690. doi: 10.3324/haematol.2017.169862. Epub 2017 Jul 27.
3
Eltrombopag Added to Standard Immunosuppression for Aplastic Anemia.艾曲泊帕添加至标准免疫抑制方案用于治疗再生障碍性贫血
N Engl J Med. 2017 Apr 20;376(16):1540-1550. doi: 10.1056/NEJMoa1613878.
4
Guidelines for the diagnosis and management of adult aplastic anaemia.成人再生障碍性贫血诊断与治疗指南。
Br J Haematol. 2016 Jan;172(2):187-207. doi: 10.1111/bjh.13853. Epub 2015 Nov 16.
5
6
Eltrombopag restores trilineage hematopoiesis in refractory severe aplastic anemia that can be sustained on discontinuation of drug.依鲁替尼可恢复对药物停药后可维持缓解的难治性重型再生障碍性贫血的三系造血。
Blood. 2014 Mar 20;123(12):1818-25. doi: 10.1182/blood-2013-10-534743. Epub 2013 Dec 17.
7
Eltrombopag and improved hematopoiesis in refractory aplastic anemia.依鲁替尼改善再生障碍性贫血的造血功能。
N Engl J Med. 2012 Jul 5;367(1):11-9. doi: 10.1056/NEJMoa1200931.
8
Prospective study of rabbit antithymocyte globulin and cyclosporine for aplastic anemia from the EBMT Severe Aplastic Anaemia Working Party.来自 EBMT 严重再生障碍性贫血工作组的兔抗胸腺球蛋白和环孢素治疗再生障碍性贫血的前瞻性研究。
Blood. 2012 Jun 7;119(23):5391-6. doi: 10.1182/blood-2012-02-407684. Epub 2012 Apr 27.
9
Critical role of thrombopoietin in maintaining adult quiescent hematopoietic stem cells.血小板生成素在维持成年静止造血干细胞中的关键作用。
Cell Stem Cell. 2007 Dec 13;1(6):671-84. doi: 10.1016/j.stem.2007.10.008. Epub 2007 Nov 20.
Zotero 插件